These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

762 related items for PubMed ID: 29544483

  • 1. N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study.
    Ide K, Koshizaka M, Tokuyama H, Tokuyama T, Ishikawa T, Maezawa Y, Takemoto M, Yokote K.
    Lipids Health Dis; 2018 Mar 15; 17(1):51. PubMed ID: 29544483
    [Abstract] [Full Text] [Related]

  • 2. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
    Dunbar RL, Nicholls SJ, Maki KC, Roth EM, Orloff DG, Curcio D, Johnson J, Kling D, Davidson MH.
    Lipids Health Dis; 2015 Sep 02; 14():98. PubMed ID: 26328624
    [Abstract] [Full Text] [Related]

  • 3. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study).
    Ballantyne CM, Braeckman RA, Bays HE, Kastelein JJ, Otvos JD, Stirtan WG, Doyle RT, Soni PN, Juliano RA.
    J Clin Lipidol; 2015 Sep 02; 9(3):377-83. PubMed ID: 26073397
    [Abstract] [Full Text] [Related]

  • 4. Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial.
    Dugani SB, Akinkuolie AO, Paynter N, Glynn RJ, Ridker PM, Mora S.
    JAMA Cardiol; 2016 May 01; 1(2):136-45. PubMed ID: 27347563
    [Abstract] [Full Text] [Related]

  • 5. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).
    Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN.
    J Clin Lipidol; 2012 May 01; 6(6):565-72. PubMed ID: 23312052
    [Abstract] [Full Text] [Related]

  • 6. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.
    Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN.
    Cardiovasc Diabetol; 2013 Jul 09; 12():100. PubMed ID: 23835245
    [Abstract] [Full Text] [Related]

  • 7. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
    Maki KC, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Curcio D, Johnson J, Kling D, Davidson MH.
    Clin Ther; 2013 Sep 09; 35(9):1400-11.e1-3. PubMed ID: 23998969
    [Abstract] [Full Text] [Related]

  • 8. N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial.
    Dogay Us G, Mushtaq S.
    Lipids Health Dis; 2022 Sep 01; 21(1):84. PubMed ID: 36050695
    [Abstract] [Full Text] [Related]

  • 9. A Randomized Trial of ω-3 Fatty Acid Supplementation and Circulating Lipoprotein Subclasses in Healthy Older Adults.
    Moosavi D, Vuckovic I, Kunz HE, Lanza IR.
    J Nutr; 2022 Jul 06; 152(7):1675-1689. PubMed ID: 35389487
    [Abstract] [Full Text] [Related]

  • 10. Peroxisome proliferator-activated receptor-gamma agonist increases both low-density lipoprotein cholesterol particle size and small high-density lipoprotein cholesterol in patients with type 2 diabetes independent of diabetic control.
    Bavirti S, Ghanaat F, Tayek JA.
    Endocr Pract; 2003 Jul 06; 9(6):487-93. PubMed ID: 14715475
    [Abstract] [Full Text] [Related]

  • 11. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.
    Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Ridker PM, Ray KK, Katona BG, Himmelmann A, Loss LE, Rensfeldt M, Lundström T, Agrawal R, Menon V, Wolski K, Nissen SE.
    JAMA; 2020 Dec 08; 324(22):2268-2280. PubMed ID: 33190147
    [Abstract] [Full Text] [Related]

  • 12. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance.
    Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, Jenkins AJ, Klein RL, Liao Y.
    Diabetes; 2003 Feb 08; 52(2):453-62. PubMed ID: 12540621
    [Abstract] [Full Text] [Related]

  • 13. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
    Maki KC, Bays HE, Dicklin MR, Johnson SL, Shabbout M.
    J Clin Lipidol; 2011 Feb 08; 5(6):483-92. PubMed ID: 22108152
    [Abstract] [Full Text] [Related]

  • 14. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L, Buysschaert M, Hermans MP.
    J Clin Lipidol; 2012 Feb 08; 6(5):434-42. PubMed ID: 23009779
    [Abstract] [Full Text] [Related]

  • 15. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.
    Pontrelli L, Parris W, Adeli K, Cheung RC.
    Metabolism; 2002 Mar 08; 51(3):334-42. PubMed ID: 11887170
    [Abstract] [Full Text] [Related]

  • 16. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW.
    Am J Cardiovasc Drugs; 2005 Mar 08; 5(6):379-87. PubMed ID: 16259526
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
    Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN.
    Am J Cardiol; 2012 Oct 01; 110(7):984-92. PubMed ID: 22819432
    [Abstract] [Full Text] [Related]

  • 18. Effect of TAK-085 on Low-density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double-blind Randomized Clinical Study.
    Tatsuno I, Kudou K, Kagawa T.
    Cardiovasc Ther; 2015 Dec 01; 33(6):317-23. PubMed ID: 26222126
    [Abstract] [Full Text] [Related]

  • 19. Omega-3 fatty acid ethyl esters improve low-density lipoprotein subclasses without increasing low-density lipoprotein-cholesterol levels: A phase 4, randomized study.
    Masuda D, Miyata Y, Matsui S, Yamashita S.
    Atherosclerosis; 2020 Jan 01; 292():163-170. PubMed ID: 31809985
    [Abstract] [Full Text] [Related]

  • 20. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.
    Marston NA, Giugliano RP, Im K, Silverman MG, O'Donoghue ML, Wiviott SD, Ference BA, Sabatine MS.
    Circulation; 2019 Oct 15; 140(16):1308-1317. PubMed ID: 31530008
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.